Health Care
CymaBay Therapeutics stock drops to 2-year low after bitter NASH study data
CymaBay Therapeutics (NASDAQ: CBAY) stock fell to a two-year low of $4.82 on Tuesday after disappointing nonalcoholic steatohepatitis (NASH) trial…
Tilray stock heads downward on doubts of cannabis risks
Tilray (NASDAQ: TLRY) stock has fallen over 47% in the year so far. The stock has been on a downward…
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note,…
CVS’ stock gains as company lays out growth strategy
CVS Health’s (NYSE: CVS) shares were up 3.2% in afternoon hours as the company outlined its growth strategy and reaffirmed…
WeedMD posts wider loss in Q1 but revenue soars 192%
Medical-grade cannabis producer WeedMD Inc. reported a wider loss in the first quarter of 2019 due to higher costs and…
Veeva Systems reports stellar Q1 earnings, outlook beat estimates
Veeva Systems (NYSE: VEEV) reported yet another solid earnings beating analyst estimates. The company also raised its full-year outlook and…
Looming opioid epidemic calls for stricter drug regulation
Though the healthcare industry is slowly waking up to the hazards of opioid-based prescription drugs, their sale continues unabated across…
Soliton spikes over 50% on its decision to proceed with cellulite trials
Shares of Soliton Inc. (NASDAQ: SOLY) jumped over 50% during the morning trade on Wednesday after the medical device company…
Charlotte’s Web Holdings retains full-year outlook; to delist from CSE
Charlotte’s Web Holdings (CSE: CWEB; OTCQX: CWBHF) first-quarter results came in line with the preliminary guidance provided earlier this month.…
Earnings Preview: Charlotte’s Web to report solid Q1 results aided by multiple tailwinds
Charlotte's Web Holdings (CSE: CWEB; OTCQX: CWBHF) is planning to report its first-quarter results tomorrow after the bell. The company…
Novartis’ one-time gene therapy for spinal muscular atrophy gets FDA nod
Picture Courtesy: Novartis Zolgensma, a gene-based treatment from Novartis (NYSE: NVS) for the treatment of spinal muscular atrophy that affects…
Centene stock spikes as activist investor Third Point pushes for its sale
Shares of Centene Corp (NYSE: CNC) shot up over 3% on average volume on Friday, after it was revealed that…
Canopy Growth names Constellation Brands veteran as acting CFO
Image by Rex Medlen from Pixabay Shares of Canopy Growth Corporation (NYSE: CGC) gained over 2% on Tuesday after the…
Medtronic to announce Q4 results amidst pacemaker crisis
Medtronic (NYSE: MDT) is scheduled to report fourth-quarter 2019 financial results on Thursday, May 23, before the regular trading hours.…
Titan Pharmaceuticals posts wider-than-expected Q1 loss
Titan Pharmaceuticals (TTNP) reported a wider loss in the first quarter of 2019 due to lower revenues and higher operating…